Citation:Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, et al 2009

From Cancer Guidelines Wiki

Citation


Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009 Mar;14(3):253-63 Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/19221167.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
What is the optimal systemic therapy for stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted

Compare quality appraisals for each clinical question

Cited by

  1. What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?
  2. What is the optimal systemic therapy for stage IV inoperable NSCLC?